INmune Bio (INMB) News Today → Crypto Millionaire Says: “Buy This $11 AI Coin.” (From InvestorPlace) (Ad) Free INMB Stock Alerts $9.92 -0.10 (-1.00%) (As of 05/13/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 7:51 PM | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q1 2024 Earnings Call TranscriptMay 12 at 5:01 PM | finance.yahoo.comINmune Bio First Quarter 2024 Earnings: EPS Misses ExpectationsMay 11 at 6:15 PM | markets.businessinsider.comRobust Pipeline and Financial Stability Underpin Buy Rating for Inmune BioMay 10, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 9, 2024 | globenewswire.comINmune Bio Inc. Announces First Quarter 2024 Results and Provides Business UpdateMay 8, 2024 | americanbankingnews.comINmune Bio (NASDAQ:INMB) Stock Price Down 0.2%May 7, 2024 | finance.yahoo.comINmune Bio Inc. to Report First Quarter 2024 Financial Results and Provide a Corporate Update on Thursday, May 9May 1, 2024 | msn.comINmune Bio files for $250M mixed shelf offeringApril 30, 2024 | finance.yahoo.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer’s Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 30, 2024 | globenewswire.comINmune Bio Inc. Provides Update on Two Patients from the Phase 1b Alzheimer's Disease Trial who Continue to Receive XPro™ Under Compassionate Use for Over Three YearsApril 29, 2024 | globenewswire.comINmune Bio Inc. Completes First Cohort and Initiates Second Cohort of Phase 1/2 Study of INKmune™ Natural Killer Cell Therapy in Patients with Metastatic Castration-Resistant Prostate CancerApril 26, 2024 | finance.yahoo.comINmune Bio Independent Director Acquires 80% More StockApril 25, 2024 | markets.businessinsider.comInmune Bio Earns Buy Rating on Positive XPro Developments and Strong FinancialsApril 25, 2024 | globenewswire.comINmune Bio Inc. Announces $9.7 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesApril 23, 2024 | globenewswire.comINmune Bio Inc. Announces 24-Month Stability Validation of XPro™ for Phase III Readiness and Commercial Supply Chain Modeling & Development of Novel Immunogenicity AssayApril 22, 2024 | msn.comINmune Bio rises 2%, on $4.5M direct offeringApril 22, 2024 | finance.yahoo.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 22, 2024 | globenewswire.comINmune Bio Inc. Raises Approximately $4.8 Million in Gross Proceeds Through Registered Direct Offering with Officers, Employees and Directors Purchasing Approximately 20% of the OfferingApril 8, 2024 | finance.yahoo.comINmune Bio Inc. Presents Data on INB03’s Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 8, 2024 | globenewswire.comINmune Bio Inc. Presents Data on INB03's Role as an Immune Check Point Modulator in the Treatment of High-Risk Breast Cancer at AACR 2024April 2, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Roivant Sciences (ROIV) and Inmune Bio (INMB)April 1, 2024 | finance.yahoo.comINmune Bio, Inc. (NASDAQ:INMB) Q4 2023 Earnings Call TranscriptMarch 31, 2024 | finance.yahoo.comINmune Bio Full Year 2023 Earnings: Revenues Beat Expectations, EPS LagsMarch 30, 2024 | seekingalpha.comINmune Bio, Inc. (INMB) Q4 2023 Earnings Call TranscriptMarch 29, 2024 | finance.yahoo.comINmune Bio Inc (INMB) Posts Year-End Earnings, Reveals Net Loss Amidst Clinical AdvancementsMarch 29, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateMarch 28, 2024 | globenewswire.comINmune Bio Inc. Announces Year End 2023 Results and Provides a Q4 Business UpdateMarch 26, 2024 | globenewswire.comINmune Bio Inc. to Report Fourth Quarter 2023 Financial Results and Provide a Corporate Update on Thursday, March 28March 13, 2024 | globenewswire.comINmune Bio CSO and Co-Founder Mark Lowdell, Ph.D. Receives The ISCT Career Achievement Award in Cell and Gene TherapyMarch 6, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XProMarch 6, 2024 | markets.businessinsider.comBuy Rating Affirmed for Inmune Bio Amid Promising Alzheimer’s Treatment DevelopmentsMarch 5, 2024 | globenewswire.comINmune Bio Reports Significant EEG Improvement in Alzheimer's Patients Treated with XPro™February 28, 2024 | marketbeat.comINmune Bio (INMB) Set to Announce Earnings on ThursdayINmune Bio (NASDAQ:INMB) will be releasing earnings on Thursday, February 29, Yahoo Finance reports.February 17, 2024 | finance.yahoo.comINMB Jun 2024 25.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 20.000 callFebruary 16, 2024 | finance.yahoo.comINMB Mar 2024 12.500 putFebruary 15, 2024 | finance.yahoo.comINMB Feb 2024 15.000 putFebruary 12, 2024 | marketbeat.comRhenman & Partners Asset Management AB Decreases Stock Position in INmune Bio, Inc. (NASDAQ:INMB)Rhenman & Partners Asset Management AB cut its holdings in INmune Bio, Inc. (NASDAQ:INMB - Free Report) by 72.0% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 50,000 shares of the company's stock afFebruary 12, 2024 | finance.yahoo.comINmune Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFebruary 7, 2024 | finance.yahoo.comINmune Bio to Participate in Baird’s Biotech Discovery Series Webcast on February 13, 2024February 4, 2024 | finance.yahoo.comInsiders own 24% of INmune Bio, Inc. (NASDAQ:INMB) shares but retail investors control 53% of the companyFebruary 1, 2024 | markets.businessinsider.comBuy Rating Affirmed: Inmune Bio’s XPro Progresses with FDA’s Green Light and Unique Therapeutic ApproachFebruary 1, 2024 | msn.comInmune Bio Resumes Alzheimer’s Trial, Aims for Mid-2024 EnrollmentJanuary 31, 2024 | msn.comFDA lifts clinical hold on INmune Bio’s Phase II Alzheimer’s trialJanuary 31, 2024 | markets.businessinsider.comInmune Bio’s Buy Rating Affirmed Amid Positive Alzheimer’s Program DevelopmentsJanuary 31, 2024 | es.investing.comINmune Bio Inc (INMB)January 31, 2024 | bizjournals.comFDA lifts hold on local company's clinical trial for Alzheimer's drugJanuary 30, 2024 | finanznachrichten.deINmune Bio, Inc.: INmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease ProgramJanuary 30, 2024 | marketwatch.comFDA Lifts Clinical Hold on INmune Bio Alzheimer's ProgramJanuary 30, 2024 | tmcnet.comINmune Bio Announces FDA Removal of Clinical Hold for Alzheimer's Disease Program Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Elon’s New Device is About to Shock the World (Ad)Using this device you see above… Elon Musk just tested a new type of A.I. that according to Wired Magazine will usher in… “The next step in human evolution.” Click here to see the details because there’s a lot of money at stake. INMB Media Mentions By Week INMB Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. INMB News Sentiment▼-0.030.57▲Average Medical News Sentiment INMB News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. INMB Articles This Week▼102▲INMB Articles Average Week Get INmune Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for INMB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Acumen Pharmaceuticals News Today Zura Bio News Today Kodiak Sciences News Today Opthea News Today Innate Pharma News Today Adverum Biotechnologies News Today Compugen News Today Elevation Oncology News Today Century Therapeutics News Today X4 Pharmaceuticals News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:INMB) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersGuard Against the Coming Financial UpheavalPorter & CompanyElon’s New Device is About to Shock the WorldInvestorPlaceConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe only AI company you should be looking atBehind the MarketsCharles Payne Demystifies OptionsUnstoppable ProsperityForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressGold ManiaStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding INmune Bio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
